Related Experiment Video

Updated: Jul 29, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Effectiveness of postprandial Humalog in toddlers with diabetes

K S Rutledge1, H P Chase, G J Klingensmith

  • 1Department of Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.

Pediatrics
|December 31, 1997
PubMed

Insights

Giving Humalog insulin after meals effectively reduced glucose excursions in young children with type 1 diabetes. This postprandial approach enhances safety and flexibility for families managing pediatric diabetes.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Mellitus Management
  • Pharmacokinetics of Insulin Analogs

Background:

  • Type 1 diabetes in children under 5 presents unique management challenges.
  • Optimizing insulin therapy is crucial for preventing glycemic excursions and ensuring safety.
  • Rapid-acting insulin analogs offer potential for improved glycemic control.

Purpose of the Study:

  • To evaluate the efficacy of postprandial Humalog administration in children under 5 with type 1 diabetes.
  • To compare postprandial Humalog with preprandial Human Regular insulin.
  • To assess the impact of Humalog timing (pre- vs. postprandial) on glucose control.

Main Methods:

  • Comparative study involving toddlers with type 1 diabetes.
  • Insulin regimens: postprandial Humalog vs. preprandial Human Regular insulin.
  • Blood glucose monitoring at fasting and 1, 2, and 4 hours postprandially.

Main Results:

  • Significantly lower 2-hour glucose excursions with postprandial Humalog compared to preprandial Human Regular insulin.
  • No significant difference in glucose excursions when Humalog was administered before or after meals.
  • Stable long-acting insulin doses were maintained throughout the study.

Conclusions:

  • Postprandial Humalog administration is an effective strategy for managing type 1 diabetes in toddlers.
  • This approach improves safety, allows for matching insulin to food intake, and offers greater family flexibility.
  • Optimized insulin timing enhances mealtime control for young children with diabetes.
Abstract

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...